LICENSE AGREEMENT between ASTRAZENECA AB and OVID THERAPEUTICS INC. Dated as of December 30, 2021License Agreement • January 3rd, 2022 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made and entered into effective as of December 30, 2021 (the “Effective Date”) by and between AstraZeneca AB, a company incorporated in Sweden under No. 556011-7482, whose registered office is registered at SE-151 85 Södertälje, Sweden and with offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”) and Ovid Therapeutics Inc., a Delaware corporation having its principal place of business at Suite 15044, 1460 Broadway, New York, NY 10036 U.S.A. (“Licensee”). AstraZeneca and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
